PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cocktail targets Hard-to-Treat brain cancer
Disease control OngoingThis early-phase trial tests a combination of the targeted drug ibrutinib with several chemotherapy drugs (TEDDI-R) in people with primary CNS lymphoma, a rare and aggressive brain cancer. The study aims to find the safest dose of ibrutinib when used in this cocktail and to see h…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could less chemo be better? new trial aims to reduce treatment burden for brain lymphoma
Disease control OngoingThis Phase III trial tests whether a de-escalated (less intense) version of the standard MATRix chemotherapy regimen works as well for newly diagnosed primary CNS lymphoma. About 331 patients will receive either the standard four courses of MATRix or a reduced schedule with one c…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE3 • Sponsor: Klinikum Stuttgart • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo shows promise for Hard-to-Treat brain cancer
Disease control OngoingThis early-phase study tests a combination of two drugs, acalabrutinib and durvalumab, in people with primary central nervous system (CNS) lymphoma—a rare and aggressive brain cancer. The study includes up to 25 patients whose cancer has returned after prior treatment or who cann…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells with an emergency brake tested in lymphoma
Disease control OngoingThis early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The cells are engineered to target and kill cancer cells, but also include a safety switch that can be activated to reduce severe side e…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New antibody drug takes aim at Hard-to-Treat brain lymphoma
Disease control OngoingThis early-phase trial tests a new drug called GNC-038 in 7 people with relapsed or refractory central nervous system lymphoma (lymphoma that has spread to the brain or spine). The drug is a tetra-specific antibody designed to target cancer cells. The main goals are to check safe…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Brain cancer hope: new drug cocktail targets rare lymphoma
Disease control OngoingThis study tests whether adding lenalidomide or ibrutinib to standard chemotherapy (R-MPV) can improve outcomes for adults aged 18-65 with newly diagnosed primary central nervous system lymphoma. The trial has two parts: first, finding the safest dose, then randomly assigning pat…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC